Predictors of HBeAg status and hepatitis B viraemia in HIV-infected patients with chronic hepatitis B in the HAART era in Brazil

BMC Infectious Diseases

Volumn 11, Issue , 2011, Pages

  Mendes Correa, Maria C ^a,b   Pinho, João R R ^b   Gomes Gouvea, Michele S ^b   da Silva, Adriana C ^b   Guastini, Cristina F ^b   Martins, Luiz G ^c   Leite, Andréa G ^a,b   Silva, Mariliza H ^c   Gianini, Reinaldo J ^b   Uip, David E ^a  

^a FACULDADE DE MEDICINA DO ABC   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c AIDS Outpatient Clinic   (Brazil)

Author keywords

Hepatitis b virus; Hiv; Tenofovir; Virological outcome

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TENOFOVIR; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DRUG DERIVATIVE; PHOSPHONIC ACID DERIVATIVE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BRAZIL; CD4 LYMPHOCYTE COUNT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DRUG RESPONSE; DRUG USE; FEMALE; GENOTYPE; HEPATITIS B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MONOTHERAPY; RETROSPECTIVE STUDY; TREATMENT DURATION; VIREMIA; VIRUS LOAD; VIRUS REPLICATION; BLOOD; HEPATITIS B VIRUS; ISOLATION AND PURIFICATION; METHODOLOGY; MIDDLE AGED; RISK FACTOR;

ADENINE; ADULT; ALANINE TRANSAMINASE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRAZIL; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; RETROSPECTIVE STUDIES; RISK FACTORS; VIRAL LOAD; VIREMIA;

EID: 80053174503     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-11-247     Document Type: Article

References (43)

1. Thio CL. Hepatitis B and human immunodeficiency virus coinfection. Hepatology 2009, 49(5 Suppl):S138-145.
2. Mendes-Corrêa MC, Barone AA, Cavalheiro N, Tengan FM, Guastini C. Prevalence of hepatitis B and C in the sera of patients with HIV infection in São Paulo, Brazil. Revista Instituto Medicina Tropical Sao Paulo 2000, 42:81-85.
3. Monteiro MR, do Nascimento MM, Passos AD, Figueiredo JF. Soroepidemiological survey of hepatitis B vírus among HIV/AIDS patients in Belém do Pará-Brasil. Revista Sociedade Brasileira Medicina Tropical 2004, 37:27-32.
4. Souza MG, Passos AD, Machado AA, Figueiredo JF, Esmeraldino LE. HIV and hepatitis B vírus co-infection:prevalence and risk factors. Revista Sociedade Brasileira Medicina Tropical 2004, 37:391-395.
5. Tovo CV, Dos Santos DE, de Mattos AZ, de Almeida PR, de Mattos AA, Santos BR. Ambulatorial prevalence of hepatitis B and C markers in patients with human immunodeficiency virus infection in a general hospital. Arquivos de Gastroenterologia 2006, 43:73-76. 10.1590/S0004-28032006000200002, 17119657.
6. Zago AM, Machado TF, Cazarim FL, Miranda AE. Prevalence and risk factors for chronic hepatitis B in HIV patients attended at a sexually-transmitted disease clinic in Vitoria, Brazil. Brazilian Journal of Infectious Diseases 2007, 11:475-478.
7. Oliveira LH, Silva IR, Xavier BL, Cavalcanti SM. Hepatitis B infection among patients attending a sexually transmitted diseases clinic in Rio de Janeiro, Brazil. Memorias Instituto Oswaldo Cruz 2001, 96(5):635-640.
8. Portelinha Filho AM, do Nascimento CU, Tannouri TN, Ascencio EL, Bonfim R, Dandrea LA, Prestes-Carneiro LE. Seroprevalence of HBV, HCV and HIV co-infection in selected individuals from state of São Paulo, Brazil. Memorias Instituto Oswaldo Cruz 2009, 104:960-963.
9. Puoti M, Torti C, Bruno R, Filice G, Carosi G. Natural history of chronic hepatitis B in coinfected patients. Journal of Hepatology 2006, 44:S65-S70.
10. Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, Zilmer K, Vella S, Kirk O, Lundgren JD. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005, 19:593-601. 10.1097/01.aids.0000163936.99401.fe, 15802978.
11. Thio CL, Seaberg EC, Skolasky R, Phair J, Visscher B, Muñoz A, Thomas DL. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicentre Cohort Study (MACS). Lancet 2002, 360:1921-1926. 10.1016/S0140-6736(02)11913-1, 12493258.
12. Sitnik R, Paes A, Mangueira CP, Pinho JR. A real-time quantitative assay for hepatitis B DNA virus (HBV) developed to detect all HBV genotypes. Revista do Instituto de Medicina Tropical de Sao Paulo 2010, 52(3):119-24.
13. Mendes-Correa MC, Pinho JR, Locarnini S, Yuen L, Sitnik R, Santana RA, Gomes-Gouvêa MS, Leite OM, Martins LG, Silva MH, Gianini RJ, Uip DE. High frequency of lamivudine resistance mutations in Brazilian patients co-infected with HIV and hepatitis B. Journal of Medical Virology 2010, 82(9):1481-1488. 10.1002/jmv.21845, 20648600.
14. Silva AC, Spina AM, Lemos MF, Oba IT, Guastini Cde F, Gomes-Gouvêa MS, Pinho JR, Mendes-Correa MC. Hepatitis B genotype G and high frequency of lamivudine-resistance mutations among human immunodeficiency virus/hepatitis B virus co-infected patients in Brazil. Memorias do Instituto Oswaldo Cruz 2010, 105(6):770-778. 10.1590/S0074-02762010000600007, 20944991.
15. Sitnik R, Pinho JR, Bertolini DA, Bernardini AP, Da Silva LC, Carrilho FJ. Hepatitis B virus genotypes and precore and core mutants in Brazilian patients. Journal of Clinical Microbiology 2004, 42(6):2455-2460. 10.1128/JCM.42.6.2455-2460.2004, 427827, 15184419.
16. Gomes-Gouvêa MS, Soares MC, Bensabath G, de Carvalho-Mello IM, Brito EM, Souza OS, Queiroz AT, Carrilho FJ, Pinho JR. Hepatitis B and Delta virus genotypes in Outbreaks of fulminant Hepatitis (Labrea black fever) in the Western Brazilian Amazon region. Journal of General Virology 2009, 90(11):2638-2643. 10.1099/vir.0.013615-0, 19605587.
17. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006, 130:678-686. 10.1053/j.gastro.2005.11.016, 16530509.
18. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. Journal of American Medical Association 2006, 295:65-73.
19. European Association for the Study of the Liver EASL clinical practice guidelines: management of chronic hepatitis B. Journal of Hepatology 2009, 50:227-242. 10.1016/j.jhep.2008.10.001, 19054588, European Association for the Study of the Liver.
20. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009, 50(3):661-662. 10.1002/hep.23190, 19714720.
21. Iser DM, Lewin SR. Future directions in the treatment of HIV-HBV co-infection. HIV Therapy 2009, 3(4):405-415. 10.2217/hiv.09.19, 2783662, 20161405.
22. Mendes-Corrêa M, Núñez M. Management of HIV and hepatitis virus co-infection. Expert Opinion on Pharmacotherapy 2010, 11(15):2497-2516. 10.1517/14656566.2010.500615, 20629586.
23. Lacombe K, Boyd A, Gozlan J, Lavocat F, Girard PM, Zoulim F. Drug-resistant and immune- escape HBV mutants in HIV-infected hosts. Antiviral Therapy 2010, 15:493-497. 10.3851/IMP1495, 20516570.
24. Lada O, Gervais A, Branger M. De novo combination therapy of tenofovir disoproxil fumarate (TDF) plus lamivudine (LAM) or TDF plus emtricitabine (FTC) is associated with early virologic response in HIV/HBV co-infected patients. 59th Annual Meeting of the American Association for the Study of Liver Diseases 2008, San Francisco, CA, [Abstract 922].
25. Tuma P, Bottecchia M, Sheldon J, Soriano V. Prior lamivudine (LAM) failure may delay time to complete HBV-DNA suppression in HIV patients treated with tenofovir plus LAM. 59th Annual Meeting of the American Association for the Study of Liver Diseases 2008, San Francisco, CA, [Abstract 967].
26. Lacombe K, Gozlan J, Boyd A, et al. HBV blippers and rebounders under treatment with tenofovir in HIV/HBV co-infection. Conference on Retrovirus and Opportunistic Infections 2009, San Francisco, CA, [Abstract 100].
27. Alvarez-Uria G, Ratcliffe L, Vilar J. Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV-coinfected cohort. HIV Medicine 2009, 10(5):269-273. 10.1111/j.1468-1293.2008.00683.x, 19210695.
28. Benhamou Y, Fleury H, Trimoulet P, Pellegrin I, Urbinelli R, Katlama C, Rozenbaum W, Le Teuff G, Trylesinski A, Piketty C. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology 2006, 43(3):548-555. 10.1002/hep.21055, 16496322.
29. Quiros-Roldan E, Calabresi A, Lapadula G, Tirelli V, Costarelli S, Cologni G, Zaltron S, Puoti M, Carosi G, Torti C. Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients co-infected by HIV. Antiviral Therapy 2008, 13(3):341-348.
30. Sitnik R, Sette H, Santana RA, Menezes LC, Graça CH, Dastoli GT, Silbert S, Pinho JR. Hepatitis B virus genotype E detected in Brazil in an African patient who is a frequent traveler. Brazilian Journal of Medical and Biological Research 2007, 40(12):1689-1692. 10.1590/S0100-879X2006005000185, 17934636.
31. Jai Jain MK, Comanor L, White C, Kipnis P, Elkin C, Leung K, Ocampo A, Attar N, Keiser P, Lee WM. Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-co-infected patients: factors associated with response. Journal Viral Hepatitis 2007, 14(3):176-182.
32. Sanchez LV, Tanaka Y, Maldonado M, Mizokami M, Panduro A. Difference of hepatitis B virus genotype distribution in two groups of mexican patients with different risk factors. High prevalence of genotype H and G. Intervirology 2007, 50:9-15. 10.1159/000096307, 17164552.
33. Lee T, Núñez M. Longer duration of HBV-active antiretroviral therapy is linked to favorable virological outcome in HIV-HBV co-infected patients. HIV Clin Trials 2009, 10(3):153-159. 10.1310/hct1003-153, 19632954.
34. Piroth L, Sène D, Pol S, Goderel I, Lacombe K, Martha B, Rey D, Loustau-Ratti V, Bergmann JF, Pialoux G, Gervais A, Lascoux-Combe C, Carrat F, Cacoub P. Epidemiology, diagnosis and treatment of chronic hepatitis B in HIV-infected patients (EPIB 2005 STUDY). AIDS 2007, 21(10):1323-1331. 10.1097/QAD.0b013e32810c8bcf, 17545709.
35. Matthews GV, Seaberg E, Dore GJ, Bowden S, Lewin SR, Sasadeusz J, Marks P, Goodman Z, Philp FH, Tang Y, Locarnini S, Thio CL. Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV co-infected individuals. AIDS 2009, 23(13):1707-1715. 10.1097/QAD.0b013e32832b43f2, 2918388, 19584701.
36. Schmutz G, Nelson M, Lutz T, Sheldon J, Bruno R, von Boemmel F, Hoffmann C, Rockstroh J, Stoehr A, Wolf E, Soriano V, Berger F, Berg T, Carlebach A, Schwarze-Zander C, Schürmann D, Jaeger H, Mauss S. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. AIDS 2006, 20:1951-1954. 10.1097/01.aids.0000247116.89455.5d, 16988516.
37. Avihingsanon A, Lewin SR, Kerr S, Chang JJ, Piyawat K, Napissanant N, Matthews GV, Dore GJ, Bowden S, Lange J, Ruxrungtham K. Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naive HIV-HBV coinfection in Thailand. Antiviral Therapy 2010, 15(6):917-922. 10.3851/IMP1645, 20834105.
38. Matthews GV, Avihingsanon A, Lewin SR, Amin J, Rerknimitr R, Petcharapirat P, Marks P, Sasadeusz J, Cooper DA, Bowden S, Locarnini S, Ruxrungtham K, Dore GJ. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand. Hepatology 2008, 48(4):1062-1069. 10.1002/hep.22462, 18697216.
39. Peters MG, Andersen J, Lynch P, Liu T, Alston-Smith B, Brosgart CL, Jacobson JM, Johnson VA, Pollard RB, Rooney JF, Sherman KE, Swindells S, Polsky B. Randomized controlled study of tenofovir and adefovir in chronic hepatitisB virus and HIV infection: ACTG A5127. HEPATOLOGY 2006, 44:1110-1116. 10.1002/hep.21388, 17058225.
40. Bodsworth N, Donovan B, Nightingale BN. The effect of concurrent human immunodeficiency virus infection on chronic hepatitis B: a study of 150 homosexual men. Journal of Infectious Diseases 1989, 160:577-582. 10.1093/infdis/160.4.577, 2571646.
41. Bonacini M, Govindarajan S, Redeker AG. Human immunodeficiency virus infection does not alter serum transaminases and hepatitis B virus (HBV) DNA in homosexual patients with chronic HBV infection. American Journal of Gastroenterology 1991, 86(5):570-573.
42. Soriano V, Vispo E, Labarga P, Medrano J, Barreiro P. Viral hepatitis and HIV co-infection. Antiviral Research 2010, 85(1):303-315. 10.1016/j.antiviral.2009.10.021, 19887087.
43. Gomes-Gouvêa MS, Pereira Soares Mdo C, Guedes de Carvalho Mello IM, Brito EM, Pereira Moia Lde J, Bensabath G, Nunes HM, Carrilho FJ, Pinho JR. Hepatitis D and B virus genotypes in chronically infected patients from the Eastern Amazon Basin. Acta Tropica 2008, 106:149-155. 10.1016/j.actatropica.2008.02.009, 18420172.